

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab-SciCrunch.org) on May 22, 2025

NOD-scid IL2R³null (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)

RRID:BCBC_4142

Type: Organism

Proper Citation

RRID:BCBC_4142

Organism Information

URL:

Proper Citation: RRID:BCBC_4142

Species: Mus musculus

Phenotype: Diabetes mellitus

Catalog Number: 4142

Background: TM

Database: BCBC, Beta Cell Biology Consortium

Database Abbreviation: BCBC

Organism Name: NOD-scid IL2R³null (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ)

Record Creation Time: 20230226T042341+0000

Record Last Update: 20250420T013609+0000

Ratings and Alerts

No rating or validation information has been found for NOD-scid IL2R³null (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ).

No alerts have been found for NOD-scid IL2R³null (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ).

Data and Source Information

Source: [Integrated Animals](#)

Source Database: BCBC, Beta Cell Biology Consortium

Usage and Citation Metrics

We found 156 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Mijit M, et al. (2024) In vitro and In vivo evidence demonstrating chronic absence of Ref-1 Cysteine 65 impacts Ref-1 folding configuration, redox signaling, proliferation and metastasis in pancreatic cancer. Redox biology, 69, 102977.

DuCote TJ, et al. (2024) EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas. Cancer research communications, 4(2), 388.

Rodrigues JS, et al. (2024) dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe. Nature communications, 15(1), 3736.

Iyer RS, et al. (2024) Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers. Nature communications, 15(1), 2130.

Lind J, et al. (2024) Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity. Blood cancer journal, 14(1), 138.

Eguren-Santamaria I, et al. (2024) MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers. Journal for immunotherapy of cancer, 12(9).

Shrestha N, et al. (2024) A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy. Cancer immunology, immunotherapy : CII, 73(9), 179.

Obajdin J, et al. (2024) Solid tumor immunotherapy using NKG2D-based adaptor CAR T cells. Cell reports. Medicine, 5(11), 101827.

Wang S, et al. (2024) Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. The Journal of clinical investigation, 134(22).

Zoine JT, et al. (2024) Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity. Cell reports. Medicine, 5(2), 101422.

Peng BJ, et al. (2024) Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease. Molecular therapy.

Methods & clinical development, 32(2), 101267.

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. *Cell reports. Medicine*, 5(3), 101469.

Nagy L, et al. (2024) Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC. *Frontiers in immunology*, 15, 1365172.

Chen K, et al. (2024) An Innovative Mitochondrial-targeted Gene Therapy for Cancer Treatment. *bioRxiv : the preprint server for biology*.

Park HB, et al. (2024) Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters. *Nature communications*, 15(1), 9917.

Wassenaar EC, et al. (2024) A unique interplay of access and selection shapes peritoneal metastasis evolution in colorectal cancer. *bioRxiv : the preprint server for biology*.

Baker CN, et al. (2024) Characterization of Collaborative Cross mouse founder strain CAST/EiJ as a novel model for lethal COVID-19. *Scientific reports*, 14(1), 25147.

Jo Y, et al. (2024) Targeting ROS-sensing Nrf2 potentiates anti-tumor immunity of intratumoral CD8⁺ T and CAR-T cells. *Molecular therapy : the journal of the American Society of Gene Therapy*, 32(11), 3879.

Safi R, et al. (2024) Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells. *Nature communications*, 15(1), 7675.

Huang T, et al. (2024) A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia. *PloS one*, 19(1), e0292375.